2020 July 29
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine To Treat Recurrent Respiratory Papillomatosis
To learn more go to: Inovio RRP Clincal Trial 2020
Inovio Pharmaceuticals is now enrolling RRP patients for a clinical trial to investigate the efficacy of a new immunotherapeutic drug. Please see the following sites for more information:
2018 Nov – New Immunotherapy trial for Adults with RRP at NIH – recruiting new patients. For more details
2018 Immunological/Genetic Juvenile RRP research study at Mass Eye & Ear and Mass General Hospital
For more details
NIDCD trial for aggressive RRP patients over 18 years old using anti-PD-L1 antibody therapy. – Completed
See announcement to RRP practitioners – August 9, 2016.
Connect with fellow patients on our Facebook page, be part of an international RRP Registry, and learn about adjunctive RRP therapies.
RRPF Pamphlet - An RRP Patient's Guide
To read about the potential role of anti-PDL-1 therapy for aggressive RRP, go to "Publications, Resources and Links"
Find an RRP Practitioner near you! A complete listing of practitioners around the world is listed.
Are you a kid who has been diagnosed with RRP? Check out materials made special for you.
See featured patient profiles of those who have gone into remission and are doing well.
Browse our library of publications and materials to start learning more about RRP.
The Recurrent Respiratory Papillomatosis Foundation was created to provide patient/family support, serve as an information resource for patients and practitioners, promote public awareness, and aid in the prevention, cure and treatment of RRP by encouraging and participating in promising RRP research studies.
Learn more the RRP Foundation